Showing results (11-20 of 108) with videos related to

Sort By:
Pageof 11
Critical Reviews in Oncology/Hematology|May 17, 2019
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastasesSantiago Ponce, Jordi Bruna, Oscar Juan, et al.
Plos One|March 17, 2015
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 14, 2018
Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patientsMarcos Nieves Sedano, José Manuel Caro Teller, Carmen García Muñoz, et al.
Journal for Immunotherapy of Cancer|May 3, 2024
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsLaurent Mathiot, David Combarel, Justin Cagnat, et al.
Clinical Lung Cancer|September 29, 2019
Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to NivolumabM Teresa Agulló-Ortuño, Óscar Gómez-Martín, Santiago Ponce, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 19, 2018
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinomaIrene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 4, 2015
SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptanRamón De Las Peñas, Santiago Ponce, Fernando Henao, et al.
Scientific Reports|February 7, 2018
The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin InductionÁlvaro Quintanal-Villalonga, Laura Ojeda-Márquez, Ángela Marrugal, et al.
Medical Oncology (Northwood, London, England)|August 29, 2016
Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancerAnalia Rodríguez Garzotto, C Vanesa Díaz-García, Alba Agudo-López, et al.
Pageof 11